Pfizer Inc. revealed encouraging topline outcomes from the Phase 3 AFFINE trial, which assesses giroctocogene fitelparvovec.

The FDA approved the combination of albuterol and budesonide under the brand name Airsupra on January 10, 2023.

This trial aims to assess the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5.

Lecanemab, marketed under the brand name Leqembi, was granted accelerated approval by the FDA on January 6, 2023.

Jul 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Ublituximab, marketed under the brand name Briumvi, is a CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). Ublituximab was approved by the FDA on December 28, 2022.

Rhythm Pharmaceuticals Begins Dosing First Patients in Phase 2 Trial for Oral MC4R Agonist LB54640 Targeting Hypothalamic Obesity.

Xenoview received FDA approval on December 23, 2022. It plays a crucial role in providing clearer images of certain areas of the body, particularly the lungs, without the need for radiation exposure.

Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis.

Adstiladrin received FDA approval on December 16, 2022. It represents a significant advancement in cancer therapy, particularly for patients who have not responded to standard treatments.

Jul 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Adagrasib, marketed under the brand name Krazati, is an oral medication used to treat adults with non-small cell lung cancer (NSCLC).